AR111182A1 - Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso - Google Patents

Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso

Info

Publication number
AR111182A1
AR111182A1 ARP180100611A ARP180100611A AR111182A1 AR 111182 A1 AR111182 A1 AR 111182A1 AR P180100611 A ARP180100611 A AR P180100611A AR P180100611 A ARP180100611 A AR P180100611A AR 111182 A1 AR111182 A1 AR 111182A1
Authority
AR
Argentina
Prior art keywords
deutetrabenazine
pharmaceutical composition
formula
compound
determination made
Prior art date
Application number
ARP180100611A
Other languages
English (en)
Spanish (es)
Inventor
Chengzhi Zhang
James Kerr
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61873991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR111182A1 publication Critical patent/AR111182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
ARP180100611A 2017-03-15 2018-03-15 Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso AR111182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15

Publications (1)

Publication Number Publication Date
AR111182A1 true AR111182A1 (es) 2019-06-12

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100611A AR111182A1 (es) 2017-03-15 2018-03-15 Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso

Country Status (20)

Country Link
US (5) US11813232B2 (cg-RX-API-DMAC10.html)
EP (1) EP3596077A1 (cg-RX-API-DMAC10.html)
JP (3) JP7608050B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200003791A (cg-RX-API-DMAC10.html)
CN (1) CN110709398A (cg-RX-API-DMAC10.html)
AR (1) AR111182A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018236336B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019018966A2 (cg-RX-API-DMAC10.html)
CA (1) CA3056612A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019002629A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019011271A2 (cg-RX-API-DMAC10.html)
EA (1) EA201992168A1 (cg-RX-API-DMAC10.html)
IL (1) IL269132A (cg-RX-API-DMAC10.html)
MX (1) MX2019010913A (cg-RX-API-DMAC10.html)
PE (1) PE20191819A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201908477QA (cg-RX-API-DMAC10.html)
TW (1) TWI772382B (cg-RX-API-DMAC10.html)
UA (1) UA127052C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018170214A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201906326B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
CN115916154A (zh) * 2020-06-10 2023-04-04 奥斯佩克斯医药公司 包括氘代丁苯那嗪的渗透剂型及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途

Also Published As

Publication number Publication date
NZ757789A (en) 2024-08-30
JP2020510073A (ja) 2020-04-02
JP2024050724A (ja) 2024-04-10
BR112019018966A2 (pt) 2020-04-22
JP7608050B2 (ja) 2025-01-06
US20220088006A1 (en) 2022-03-24
JP2023010754A (ja) 2023-01-20
CA3056612A1 (en) 2018-09-20
IL269132A (en) 2019-11-28
US11813232B2 (en) 2023-11-14
US12502385B2 (en) 2025-12-23
US20200016148A1 (en) 2020-01-16
EP3596077A1 (en) 2020-01-22
PE20191819A1 (es) 2019-12-27
JP7631572B2 (ja) 2025-02-18
WO2018170214A1 (en) 2018-09-20
TWI772382B (zh) 2022-08-01
UA127052C2 (uk) 2023-03-29
AU2018236336B2 (en) 2022-02-24
US20260144785A1 (en) 2026-05-28
TW201840317A (zh) 2018-11-16
MX2019010913A (es) 2020-01-20
CO2019011271A2 (es) 2020-02-28
KR20230003308A (ko) 2023-01-05
EA201992168A1 (ru) 2020-03-16
CN110709398A (zh) 2020-01-17
KR20200003791A (ko) 2020-01-10
US20220040170A1 (en) 2022-02-10
AU2022203369A1 (en) 2022-06-09
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
US20180263972A1 (en) 2018-09-20
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21
US11179386B2 (en) 2021-11-23
AU2022203369B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US11364252B2 (en) System and method for diagnosis and treatment
US20230265193A1 (en) Pd-1 signal inhibitor combination therapy
EP3184519A1 (en) ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
MX385265B (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
Gros et al. Pharmacological regulators of autophagy and their link with modulators of lupus disease
Feng et al. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition
CL2018003178A1 (es) Composición farmacéutica
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CY1124104T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AR079836A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
BRPI0512660A (pt) tablete carregável, e, método para a preparação de um tablete
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
CR20210318A (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
TR200401436T4 (tr) Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
PE20191819A1 (es) Analogos de deutetrabenazina, su preparacion y uso
AR048501A1 (es) Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
MX2024013176A (es) Nuevos anticuerpos anti proteina 3 similar a la angiopoyetina (angptl3) adecuados para composiciones de concentracion alta y administracion subcutanea
BR112013026755A2 (pt) derivados da acadesina, produtos e composições que os compreendem, as respectivas utilizações terapêuticas e os respectivos processos de síntese
UY28910A1 (es) Prodrogas de estriol y estetrol
Lee et al. Development of 1‐Amino‐4‐(phenylamino) anthraquinone‐2‐sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL‐Induced Osteoclastogenesis
CN104840465B (zh) 一种氟马西尼注射液及其制备方法

Legal Events

Date Code Title Description
FC Refusal